A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
← catalyst calendarSponsored by Evommune, Inc. (industry) · EVMN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30actual
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-14 | actual | When the study began enrolling |
| Primary completion | 2025-05-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-08 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | 2026-05-19 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Inducible Urticaria
Interventions
- Drug: Oral EVO756 300 mg QD
- Drug: Oral EVO756 50 mg BID
Primary outcome
what the primary-completion date above is the date OFSafety and Tolerability
measured Day 1 to Week 6
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-01-10 · 2.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-04-14 · 3.4 MB · SAP_001.pdf
Permalink · EVMN's whole pipeline · Catalyst calendar · Every registered study · What changed